Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
SOUTH SAN FRANCISCO, Calif. and ANN ARBOR, Mich., June 22, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (“Tempest”), a clinical-stage oncology company developing potentially...
– Transaction to advance Tempest’s targeted oncology pipeline – - Concurrent $30M PIPE financing expected to close with merger - - Companies to host conference call today at 8:30 a.m. ET...
– Further investment in MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist, not planned following initial review of data from Phase 1 clinical study – – Company exploring expanded...
– Phase 1 clinical trial underway for MLE-301, a selective NK3R antagonist being studied for the treatment of vasomotor symptoms (VMS) in menopausal women – Millendo Therapeutics, Inc. (Nasdaq:...
– First subject dosed with MLE-301, for the treatment of vasomotor symptoms (VMS) in menopausal women – – Phase 1 study will evaluate safety, pharmacokinetics and preliminary efficacy...
Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, today...
– Phase 1 clinical trial to initiate in 3Q20 for MLE-301, a selective NK3R antagonist being studied for the treatment of vasomotor symptoms (VMS) in menopausal women – Millendo Therapeutics...
Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs...
– MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist, advancing with first-in-human trials expected to initiate in 3Q20 – – Further investment in nevanimibe for congenital adrenal...
Millendo Therapeutics, Inc. (Nasdaq:MLND), a clinical stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, today...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
